<p>Spyglass Pharma（纳斯达克代码：SGP - 获取免费报告）在周二发布给投资者的报告中被杰富瑞金融集团的投资分析师上调至 “强力买入” 评级，Marketbeat Ratings 报道。</p>
<p>获取 <strong>Spyglass Pharma</strong> 的提醒：</p>
<p>其他几位股票研究分析师最近也对 SGP 发表了看法。花旗集团在周二的一份报告中开始覆盖 Spyglass Pharma 的股票。他们给予该公司的 “买入” 评级，并设定了 42.00 美元的目标价。Leerink Partners 在周二的一份研究报告中将 Spyglass Pharma 的股票下调至 “市场表现” 评级。Stifel Nicolaus 在周二的一份报告中开始覆盖 Spyglass Pharma 的股票。他们给予该公司的 “买入” 评级，并设定了 42.00 美元的目标价。最后，华尔街 Zen 在 2 月 17 日的报告中将 Spyglass Pharma 的评级上调至 “持有”。一位投资分析师给予该股票 “强力买入” 评级，三位分析师给予该股票 “买入” 评级。根据 MarketBeat 的数据，Spyglass Pharma 的平均评级为 “买入”，平均目标价为 47.00 美元。</p>
<p><strong>查看我们关于 Spyglass Pharma 的最新报告</strong></p>
<h2>Spyglass Pharma 股票上涨 0.1%</h2>
<p>SGP 股票在周二开盘价为 26.75 美元。Spyglass Pharma 的一年低点为 20.16 美元，一年高点为 32.44 美元。</p>
<h2>内部活动</h2>
<p>在其他 Spyglass Pharma 的新闻中，董事 Ra Capital Management, L.P. 在 2 月 9 日的交易中收购了 3,690,000 股该股票。这些股票的平均购买价格为每股 16.00 美元，总价值为 59,040,000.00 美元。购买后，该董事直接持有该公司 5,966,439 股股票，估值约为 95,463,024 美元。这笔交易代表了他们持股的 162.10% 增加。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。</p>
<h2>Spyglass Pharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家晚期生物制药公司，致力于通过长期有效的药物递送改变慢性眼病患者的治疗模式。我们的使命是通过开发耐用的药物递送解决方案，显著改善慢性眼病患者的生活，使患者和外科医生在长期控制疾病和保护视力方面充满信心。我们的主要产品候选者，Bimatoprost 药物垫 IOL 系统（BIM-IOL 系统），由新型专有药物垫与我们的人工晶状体（IOL）相结合，旨在在常规白内障手术中植入，以降低患有开角型青光眼（OAG）或眼压升高（OHT）患者的眼内压（IOP）。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Spyglass Pharma</li>
<li>新发现的富铜 “克拉肯” 区</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>白银的挤压正在加紧 - 机会正在形成</li>
<li>特朗普的新行政命令 - 退休账户将迎来重大变化</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Spyglass Pharma 吗？</h2>
<p>在你考虑 Spyglass Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Spyglass Pharma 并不在名单上。</p>
<p>虽然 Spyglass Pharma 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Jefferies Financial Group 将 Spyglass Pharma (NASDAQ:SGP) 的评级上调至 “强力买入”。其他分析师也发表了看法，花旗集团给予 “买入” 评级，并设定目标价为 42 美元，而 Leerink Partners 则将该股票下调至 “市场表现”。Spyglass Pharma 的股票开盘价为 26.75 美元，1 年最低价为 20.16 美元，最高价为 32.44 美元。最近，Ra Capital Management 以每股 16 美元收购了 369 万股，增持幅度达到 162.10%。该公司专注于通过创新药物递送系统治疗慢性眼部疾病</p>

<p>Spyglass Pharma (NASDAQ:SGP - Get Free Report) was upgraded by investment analysts at Jefferies Financial Group to a &#34;strong-buy&#34; rating in a note issued to investors on Tuesday, Marketbeat Ratings reports.</p>
<div class="lb-trans"><p>Spyglass Pharma（纳斯达克代码：SGP - 获取免费报告）在周二发布给投资者的报告中被杰富瑞金融集团的投资分析师上调至 “强力买入” 评级，Marketbeat Ratings 报道。</p>
</div><p>Get <strong>Spyglass Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spyglass Pharma</strong> 的提醒：</p>
</div><p>Several other equities research analysts also recently weighed in on SGP. Citigroup started coverage on shares of Spyglass Pharma in a report on Tuesday. They issued a &#34;buy&#34; rating and a $42.00 price objective for the company. Leerink Partners downgraded shares of Spyglass Pharma to a &#34;market perform&#34; rating in a research report on Tuesday. Stifel Nicolaus began coverage on shares of Spyglass Pharma in a report on Tuesday. They issued a &#34;buy&#34; rating and a $42.00 price objective for the company. Finally, Wall Street Zen raised Spyglass Pharma to a &#34;hold&#34; rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to data from MarketBeat, Spyglass Pharma has an average rating of &#34;Buy&#34; and an average price target of $47.00.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对 SGP 发表了看法。花旗集团在周二的一份报告中开始覆盖 Spyglass Pharma 的股票。他们给予该公司的 “买入” 评级，并设定了 42.00 美元的目标价。Leerink Partners 在周二的一份研究报告中将 Spyglass Pharma 的股票下调至 “市场表现” 评级。Stifel Nicolaus 在周二的一份报告中开始覆盖 Spyglass Pharma 的股票。他们给予该公司的 “买入” 评级，并设定了 42.00 美元的目标价。最后，华尔街 Zen 在 2 月 17 日的报告中将 Spyglass Pharma 的评级上调至 “持有”。一位投资分析师给予该股票 “强力买入” 评级，三位分析师给予该股票 “买入” 评级。根据 MarketBeat 的数据，Spyglass Pharma 的平均评级为 “买入”，平均目标价为 47.00 美元。</p>
</div><p><strong>View Our Latest Report on Spyglass Pharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Spyglass Pharma 的最新报告</strong></p>
</div><h2>Spyglass Pharma Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Spyglass Pharma 股票上涨 0.1%</h2>
</div><p>Shares of SGP stock opened at $26.75 on Tuesday. Spyglass Pharma has a 1 year low of $20.16 and a 1 year high of $32.44.</p>
<div class="lb-trans"><p>SGP 股票在周二开盘价为 26.75 美元。Spyglass Pharma 的一年低点为 20.16 美元，一年高点为 32.44 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Spyglass Pharma news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of the stock in a transaction dated Monday, February 9th. The shares were bought at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the purchase, the director directly owned 5,966,439 shares of the company's stock, valued at approximately $95,463,024. This trade represents a 162.10% increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>在其他 Spyglass Pharma 的新闻中，董事 Ra Capital Management, L.P. 在 2 月 9 日的交易中收购了 3,690,000 股该股票。这些股票的平均购买价格为每股 16.00 美元，总价值为 59,040,000.00 美元。购买后，该董事直接持有该公司 5,966,439 股股票，估值约为 95,463,024 美元。这笔交易代表了他们持股的 162.10% 增加。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。</p>
</div><h2>Spyglass Pharma Company Profile</h2>
<div class="lb-trans"><h2>Spyglass Pharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).</p>
<div class="lb-trans"><p>我们是一家晚期生物制药公司，致力于通过长期有效的药物递送改变慢性眼病患者的治疗模式。我们的使命是通过开发耐用的药物递送解决方案，显著改善慢性眼病患者的生活，使患者和外科医生在长期控制疾病和保护视力方面充满信心。我们的主要产品候选者，Bimatoprost 药物垫 IOL 系统（BIM-IOL 系统），由新型专有药物垫与我们的人工晶状体（IOL）相结合，旨在在常规白内障手术中植入，以降低患有开角型青光眼（OAG）或眼压升高（OHT）患者的眼内压（IOP）。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Spyglass Pharma</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
<li>Trump's NEW Executive Order - BIG Changes Coming to Retirement Accounts</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Spyglass Pharma</li>
<li>新发现的富铜 “克拉肯” 区</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>白银的挤压正在加紧 - 机会正在形成</li>
<li>特朗普的新行政命令 - 退休账户将迎来重大变化</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spyglass Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Spyglass Pharma 吗？</h2>
</div><p>Before you consider Spyglass Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Spyglass Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Spyglass Pharma 并不在名单上。</p>
</div><p>While Spyglass Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spyglass Pharma 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SpyGlass Pharma（纳斯达克代码：SGP）的评级在 Jefferies Financial Group 被上调至强力买入